Gritstone Bio Inc - Company Profile
Powered by 
All the data and insights you need on Gritstone Bio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Gritstone Bio Inc Strategy Report
- Understand Gritstone Bio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gritstone Bio Inc (Gritstone), formerly Gritstone Oncology Inc, is a clinical-stage biotechnology company. The company discovers, develops, manufactures, and delivers vaccine-based immunotherapy candidates against cancer and infectious diseases. It develops personalized cancer vaccines designed to direct a robust immune response to neoantigens by leveraging its artificial intelligence Gritstone EDGE platform. Gritstone’s cancer vaccines product pipeline includes GRANITE and SLATE for solid tumors; and prophylactic samRNA (CORAL), HIV Therapeutic vaccine, and other flu, multi-respiratory, papillomavirus (HPV) eradication pathogens. The company designs immunotherapy containing the relevant neoantigens to be administered by intramuscular injection. It manufactures products through its biomanufacturing facilities in Massachusetts, and California, the US. Gritstone is headquartered in Emeryville, California, the US.
Headquarters
United States of America
Address
5959 Horton Street, Suite 300, Emeryville, California, 94608
Website
gritstonebio.com
Telephone
1 510 8716100
No of Employees
231
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRTS (NASD)
Revenue (2022)
$16.3M
-18.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-15.7%
(2022 vs 2021)
Market Cap*
$92.2M
Net Profit Margin (2022)
XYZ
-41.2%
(2022 vs 2021)
* As of and is in US$
Gritstone Bio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Oncology Programs: |
| GRANITE |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement of US$433 million with the Biomedical Advanced Research and Development Authority to perform a Phase 2b comparison research testing Gritstone's self-amplifying mRNA (samRNA) vaccine candidate incorporating Spike as well as additional viral targets for COVID-19 protection. |
| 2023 | Contracts/Agreements | In August, the company partnered with Friends of Cancer Research to provide foundational evidence to inform future use of change in circulating tumor DNA (ctDNA) as an early indicator of long-term clinical benefit from therapeutics in cancer patients. |
| 2023 | Contracts/Agreements | In February, the company entered into a clinical trial agreement with the National Cancer Institute to evaluate an autologous T cell therapy. |
Competitor Comparison
| Key Parameters | Gritstone Bio Inc | Moderna Inc | Equillium Inc | VBI Vaccines Inc | Transgene SA |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | France |
| City | Emeryville | Cambridge | La Jolla | Cambridge | Illkirch-Graffenstaden |
| State/Province | California | Massachusetts | California | Massachusetts | Alsace |
| No. of Employees | 231 | 5,600 | 44 | 131 | 164 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Elaine V. Jones | Chairman | Executive Board | 2020 | 68 |
| Andrew Allen | Chief Executive Officer; Director; President | Executive Board | 2015 | 56 |
| Celia Economides | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 43 |
| Erin E Jones | Executive Vice President; Chief Operating Officer | Senior Management | 2021 | 51 |
| Stacy Proctor | Senior Vice President; Head - People | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer